Transaction · 0001468308-26-000034

Andrade Robert

Andrade Robert, CFO, reported a transaction classified as grant at FENNEC PHARMACEUTICALS INC. involving 3846.000000 shares for an estimated $21268.38. Reported holdings after the transaction were 246855.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACFO
FENCFENNEC PHARMACEUTICALS INC.
Trade date
Oct 12, 2026
Filing date
Oct 13, 2026
View on SEC Insider profile
Estimated value$21.2kShares × reported price
Shares traded3.84k$5.53 per share
Holdings after246kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

FENC price since this filing

Daily closing prices, with the filing date and available return windows
FENC · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +2.2%1w ago -0.9%1d ago -0.1%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
grant
Code A
Identifier
0001468308-26-000034
Common shares
Transaction date
Oct 12, 2026
Filed Oct 13, 2026, 08:05 PM · 1d delay
Shares
3,846 sh
$5.53 per share
Estimated value
$21.2k
Computed from shares × price
Holdings after
246,855 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership
Filing-only score

-12 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 1

    Filing reported within two business days of the transaction.
  • grant_or_award-22 points

    transaction_code = A

    Grant or award transactions are scheduled compensation, not discretionary.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CHIEF FINANCIAL OFFICER

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The Issuer's common shares were acquired pursuant to the Fennec Pharmaceuticals Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 9, 2026 through October 12, 2026.

  2. F2

    In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on the Nasdaq Capital Market on April 9, 2026.

Original filing · 0001468308-26-000034
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

FENC